CELL LINE

products@integratedbiotherapeutics.com

SARS-CoV-2 Indicator Cell for RNA replication-GFP reporter

Catalog #: 001-PP-001

Description: The SARS-CoV-2 reporter cell is a proprietary technology. This first-of-its kind reporter cell represents a major advancement in the development of rapid coronavirus indicators cells. Our reporter cells carry a stably integrated reporter construct that is derived from a mini-antisense genome of SARS-CoV-2.

Authentic SARS-CoV-2 replicase proteins permit reporter expression by converting the mini-antisense genome into a positive-sense genome. The cell line is derived from Virongy's HEK293T(ACE2/TMPRSS2) cells which express high levels of ACE2 and TMPRSS2 to permit SARS-CoV-2 entry. The SARS-CoV-2 GFP reporter cells turn GFP positive upon live virus infection. The SARS-CoV-2 reporter cell line does not produce any viral proteins and does not greatly impact overall viral replication.

Formulation & Storage:

Notes & Usage Guidelines:

Key Features:

- High Sensitivity and Specificity – Minimal Background Signal
- Rapid quantification of SARS-CoV-2 infectious titer in less than 24 hours.
- No need for performing plaque assays and counting plaques
- GFP reporter for rapid and easy enumeration of infected cells with a flow cytometer or fluorescent microscope
- With enhanced accuracy – results are not affected by inaccurate plaque counting and loss of cells during cell fixing and staining.



SARS-CoV-2 Reporter cells were infected with either mock virus or authentic SARS-CoV-2. The reporter was quantified by fluorescent microscopy two days post-infection.

Certificate of analysis:
A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. For older lots, refer to the applicable certificate of analysis that may be requested at products@ibtbioservices.com.

Related Products:
IBT provides a wide array of antibodies, recombinant proteins, and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.